Analysts expect Heat Biologics, Inc. (NASDAQ:HTBX) to report $-0.14 EPS on February, 21.After having $-0.16 EPS previously, Heat Biologics, Inc.’s analysts see -12.50% EPS growth. The stock decreased 2.22% or $0.03 during the last trading session, reaching $1.32. About 205,476 shares traded. Heat Biologics, Inc. (NASDAQ:HTBX) has declined 66.75% since February 11, 2018 and is downtrending. It has underperformed by 66.75% the S&P500. Some Historical HTBX News: 26/04/2018 – BRISTOL-MYERS CEO SAYS CONTINUES TO SEE BMS AS A GROWTH COMPANY AND OPDIVO AS A GROWTH FRANCHISE; 06/03/2018 – BRISTOL-MYERS SQUIBB CO – DOSING SCHEDULE UPDATES FOR AN ADDITIONAL APPROVED INDICATION FOR OPDIVO MAY BE SUBMITTED TO FDA IN FUTURE FOR OPDIVO; 16/04/2018 – Bristol-Myers: In Phase 3 CheckMate -214 Clinical Trial, Opdivo + Yervoy Combination Demonstrated a Significant and Unprecedented Increase in Overall Survival; 16/04/2018 – BRISTOL-MYERS SQUIBB – IN PHASE 3 CHECKMATE -214 TRIAL, OPDIVO + YERVOY ALSO DELIVERED DURABLE RESPONSES, WITH HIGHER OBJECTIVE RESPONSE RATE VS SUNITINIB; 26/04/2018 – BRISTOL-MYERS SQUIBB CO – QTRLY OPDIVO WORLDWIDE REVENUE $1,511 MLN VS $1,127 MLN REPORTED LAST YEAR; 24/04/2018 – MIRATI THERAPEUTICS – SITRAVATINIB BEING EVALUATED IN PHASE 2 STUDY IN COMBINATION WITH NIVOLUMAB HAS BEEN WELL-TOLERATED; 16/04/2018 – BRISTOL-MYERS: OPDIVO PHASE 3 SHOWED BENEFIT FOR PRIMARY ENDPT; 26/04/2018 – Bristol-Myers 1Q Opdivo Revenue $1.51 Billion; 26/03/2018 – BRISTOL-MYERS SQUIBB CO – CHMP RECOMMENDATION OF OPDIVO WILL NOW BE REVIEWED BY EUROPEAN COMMISSION; 16/04/2018 – IN CHECKMATE -141, OPDIVO (NIVOLUMAB) DEMONSTRATED SUSTAINED OVERALL SURVIVAL (OS) ADVANTAGE OVER STANDARD OF CARE IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND…

C&J Energy Services Inc (NYSE:CJ) had a decrease of 20.99% in short interest. CJ’s SI was 2.99M shares in February as released by FINRA. Its down 20.99% from 3.79M shares previously. With 825,600 avg volume, 4 days are for C&J Energy Services Inc (NYSE:CJ)’s short sellers to cover CJ’s short positions. The SI to C&J Energy Services Inc’s float is 4.91%. The stock decreased 0.75% or $0.12 during the last trading session, reaching $15.82. About 554,772 shares traded. C&J Energy Services, Inc. (NYSE:CJ) has declined 53.42% since February 11, 2018 and is downtrending. It has underperformed by 53.42% the S&P500. Some Historical CJ News: 20/03/2018 – C&J ENERGY SERVICES SAYS CFO MARK CASHIOLA HAS RESIGNED; 08/05/2018 – C&J ENERGY SERVICES INC CJ.N : CITIGROUP RAISES TARGET PRICE TO $37 FROM $35; 20/03/2018 – C&J Energy Services Chief Financial Officer Mark Cashiola Resigns; 20/03/2018 – C&J ENERGY – MIKE GALVAN, CURRENTLY C&J’S SENIOR VICE PRESIDENT AND CHIEF ACCOUNTING OFFICER, WILL ASSUME ADDITIONAL ROLE OF CFO ON AN INTERIM BASIS; 25/05/2018 – C&J Energy Services Closes Below 50-Day Average: Technicals; 26/03/2018 – C&J ENERGY SERVICES INC SEES ESTIMATED 2018 CAPEX BUDGET OF $430 MLN TO $450 MLN – PRESENTATION SLIDES; 11/05/2018 – Van Eck Adds C&J. Energy Services Inc., Exits Union Pacific: 13F; 20/03/2018 – C&J ENERGY SERVICES INC CJ.N SAYS CFO MARK CASHIOLA RESIGNED; 03/05/2018 – C&J Energy Services 1Q EPS 31c; 29/03/2018 – C&J Energy Services Volume Surges More Than 10 Times Average

More notable recent Heat Biologics, Inc. (NASDAQ:HTBX) news were published by: Seekingalpha.com which released: “Dosing underway in expanded lung cancer study of Heat Biologics’ HS-110 – Seeking Alpha” on January 14, 2019, also Nasdaq.com with their article: “5 Top Gainers In Healthcare Sector (MBOT, VVUS, RNN…) – Nasdaq” published on January 14, 2019, Seekingalpha.com published: “Heat Biologics -26% on potential share sale – Seeking Alpha” on November 21, 2018. More interesting news about Heat Biologics, Inc. (NASDAQ:HTBX) were released by: Seekingalpha.com and their article: “Heat Biologics expands mid-stage study of HS-110 to include different PD-1 inhibitor – Seeking Alpha” published on January 10, 2019 as well as Streetinsider.com‘s news article titled: “Heat Biologics (HTBX) Plans Public Offering of Common Stock and Warrants – StreetInsider.com” with publication date: November 20, 2018.

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the United States. The company has market cap of $42.84 million. The firm develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. It currently has negative earnings. The Company’s product candidates include HS-110 that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase 2 clinical trials for the treatment of non-muscle invasive bladder cancer.

C&J Energy Services, Inc. provides completion and production services for gas and oil industry primarily in North America. The company has market cap of $1.07 billion. The firm provides well construction, well completions, well support, and other oilfield services to gas and oil exploration and production companies. It currently has negative earnings. It operates through Completion Services and Well Support Services divisions.

More notable recent C&J Energy Services, Inc. (NYSE:CJ) news were published by: which released: “40 Stocks Moving In Friday’s Pre-Market Session – Benzinga” on January 18, 2019, also with their article: “Benzinga’s Top Upgrades, Downgrades For December 19, 2018 – Benzinga” published on December 19, 2018, Seekingalpha.com published: “Western Digital Corporation (WDC) CEO Steve Milligan on Q2 2019 Results – Earnings Call Transcript – Seeking Alpha” on January 24, 2019. More interesting news about C&J Energy Services, Inc. (NYSE:CJ) were released by: and their article: “Morgan Stanley: C&J Energy (NYSE:CJ) Is Catching Up With The Competition – Benzinga” published on November 14, 2017 as well as Bizjournals.com‘s news article titled: “Houston energy companies announce CFO changes – Houston Business Journal” with publication date: August 17, 2018.